Concentric Analgesics has commenced a Phase ll clinical study of CA-008 for the treatment of post-surgical pain.

As part of the randomised, double-blind, placebo-controlled, dose-ranging trial, an undisclosed number of patients undergoing bunionectomy will be enrolled.

The trial’s primary objective is to examine the efficacy and safety of a single dose of CA-008 at different doses against placebo.

Findings from the trial are expected to allow Concentric to determine the precise dose of CA-008 for future clinical studies.

Concentric Analgesics chief medical officer Mike Royal said: “Our first-in-human Phase lb (Plb) bunionectomy study demonstrated that CA-008 can be administered safely to surgical patients, and the strong signal of efficacy supports its unique and compelling therapeutic profile.

“Initiating a larger Phase ll study is the next step in advancing our clinical development programme to bring CA-008 to market.”

“CA-008 has the potential to dramatically improve patient recovery and outcomes by providing long-lasting pain relief during the immediate post-operative period and throughout outpatient recovery.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData

“Initiating a larger Phase ll study is the next step in advancing our clinical development programme to bring CA-008 to market.”

The newly concluded, Phase lb placebo-controlled trial showed safety and tolerability of CA-008 across the study doses in patients undergoing bunionectomy.

CA-008 also demonstrated a statistically significant and clinically meaningful 63% reduction of pain intensity for area under the curve (AUC) at 0h-168h, as well as statistically significant reductions of pain at 48h, 72h, 96h and 120h, and nearly a 50% reduction in opioid consumption.

CA-008 is an investigational water-soluble non-opioid prodrug that can be rapidly converted to capsaicin, a potent TRPV1-agonist which selectively desensitises pain conducting nerve fibres to provide long-lasting analgesia.